InMode reported Q2 2026 earnings that beat consensus by $0.02 per share, with revenue topping Wall Street estimates. The RF microneedling and energy-device platform maker continues to benefit from steady U.S. aesthetic device demand, though margin compression concerns persist in analyst commentary.
The company's core installed base of Morpheus8 and BodyTite systems remains a revenue anchor, but competitive pressure from Cutera and other multi-modality platforms is intensifying. Steel Partners, InMode's largest shareholder, has publicly urged shareholders to vote against certain governance proposals, signaling activist pressure over capital allocation and strategic direction.